Approximately 40% of NK-AML patients harbour mutations in class III receptor tyrosine kinase either as a result of internal tandem duplication (FLT3-ITD) or substitution of the aspartic acid at position 835 with a tyrosine (FLT3-TKD) [11,12]. This evidence concerns the gene FLT3 and acute myeloid leukemia.